Dual mechanism of action
The distinctive feature of vasopeptidase inhibitors lies in their simultaneous effect on two key targets in the body:
- ACE blockade — suppresses the activity of the renin-angiotensin system, leading to the elimination of the vasopressor effect.
- Neutral endopeptidase blockade — this enzyme normally degrades endogenous vasodilating peptides. Inhibition of its activity enhances the effect of vasodilating systems.
As a result of the combined effect, blood pressure is reduced due to the simultaneous suppression of vasoconstriction and enhancement of vasodilation.
Pharmacokinetic features
The representative of the class is characterized by the following parameters:
- It has good absorption with a bioavailability of about 30%.
- The maximum concentration in the blood is reached 2 hours after administration.
- The half-life ($t_{1/2}$) ranges from 14 to 19 hours, providing a duration of action of more than 24 hours.
- Metabolites are excreted from the body by the kidneys.
Clinical status and reasons for withdrawal
Despite high efficacy in lowering blood pressure through dual blockade, the drug did not enter routine clinical practice. The main reason for abandoning its use was the high incidence of a severe adverse reaction — angioedema.
Omapatrilat: A dual blow to blood pressure (ACE + neutral endopeptidase), but dangerous edema blocks its path to the clinic.
Class and exam questions
What mechanism of action is characteristic of vasopeptidase inhibitors?
Drugs of this class have a dual mechanism of action: they simultaneously block angiotensin-converting enzyme (reducing the activity of the renin-angiotensin system) and neutral endopeptidase (preventing the degradation of endogenous vasodilating peptides).
Why is omapatrilat not used in modern clinical practice?
Despite high efficacy and prolonged action, the drug did not find clinical application due to frequent and severe adverse reactions, specifically the development of angioedema.
What are the main pharmacokinetic parameters of omapatrilat?
The drug is well absorbed (bioavailability 30%), reaches peak concentration in 2 hours, has a half-life of 14–19 hours (action lasts more than 24 hours), and is excreted by the kidneys as metabolites.
What else to study on this topic
- The role of neutral endopeptidase in the regulation of vascular tone
- Interaction of the renin-angiotensin system and vasodilating peptides
- Pharmacokinetics of omapatrilat: absorption, peak concentration, and renal clearance
- Pathogenesis of angioedema during vasopeptidase blockade
- Prospects for molecular modification to develop safe vasopeptidase blockers
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Vasopeptidase inhibitors" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Cardiovascular Drugs"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.